Adoptive Immunotherapy

Posttransplant CTL Transfer Works for Solid Tumors

Published in Vaccine Weekly, September 13th, 1999

It isn't supposed to work for solid organ recipients, but it does.

The dramatic treatment of a dying patient for the first time shows adoptive immunotherapy is possible in organ transplant recipients. Making this breakthrough all the more remarkable is that it was supposed to be impossible.

The patient originally was negative for Epstein-Barr virus (EBV) infection. After receiving a lung transplant and concomitant immunosuppressive therapy, however, he became EBV-positive and developed active posttransplant lymphoproliferative disease (PTLD). Adoptive transfer of autologous, EBV-sensitized, cytotoxic lymphocytes (CTLs) resulted in extensive...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (1999-09-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry